110 related articles for article (PubMed ID: 28956333)
1. The Past, Present, and Future of Phosphodiesterase-4 Modulation for Age-Induced Memory Loss.
Hansen RT; Zhang HT
Adv Neurobiol; 2017; 17():169-199. PubMed ID: 28956333
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 modulation as a potential therapeutic for cognitive loss in pathological and non-pathological aging: possibilities and pitfalls.
Hansen RT; Zhang HT
Curr Pharm Des; 2015; 21(3):291-302. PubMed ID: 25159075
[TBL] [Abstract][Full Text] [Related]
3. The PDE4 cAMP-Specific Phosphodiesterases: Targets for Drugs with Antidepressant and Memory-Enhancing Action.
Bolger GB
Adv Neurobiol; 2017; 17():63-102. PubMed ID: 28956330
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-4D Knock-down in the Prefrontal Cortex Alleviates Chronic Unpredictable Stress-Induced Depressive-Like Behaviors and Memory Deficits in Mice.
Wang ZZ; Yang WX; Zhang Y; Zhao N; Zhang YZ; Liu YQ; Xu Y; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Sci Rep; 2015 Jul; 5():11332. PubMed ID: 26161529
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
6. Targeting phosphodiesterase 4 as a therapeutic strategy for cognitive improvement.
Wei X; Yu G; Shen H; Luo Y; Shang T; Shen R; Xi M; Sun H
Bioorg Chem; 2023 Jan; 130():106278. PubMed ID: 36413930
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.
Tan Y; Watkins AA; Freeman BB; Meyers JA; Rifkin IR; Lerner A
J Immunol; 2015 Jan; 194(1):101-12. PubMed ID: 25416804
[TBL] [Abstract][Full Text] [Related]
8. PDE4 inhibitors for disease therapy: advances and future perspective.
Du B; Luo M; Ren C; Zhang J
Future Med Chem; 2023 Jul; 15(13):1185-1207. PubMed ID: 37470147
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase-4 inhibition as a therapeutic strategy for metabolic disorders.
Wu C; Rajagopalan S
Obes Rev; 2016 May; 17(5):429-41. PubMed ID: 26997580
[TBL] [Abstract][Full Text] [Related]
10. Role of phosphodiesterase 4-mediated cyclic AMP signaling in pharmacotherapy for substance dependence.
Wen RT; Feng WY; Liang JH; Zhang HT
Curr Pharm Des; 2015; 21(3):355-64. PubMed ID: 25159074
[TBL] [Abstract][Full Text] [Related]
11. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D.
Sierksma AS; van den Hove DL; Pfau F; Philippens M; Bruno O; Fedele E; Ricciarelli R; Steinbusch HW; Vanmierlo T; Prickaerts J
Neuropharmacology; 2014 Feb; 77():120-30. PubMed ID: 24067928
[TBL] [Abstract][Full Text] [Related]
12. The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling.
Wang G; Chen L; Pan X; Chen J; Wang L; Wang W; Cheng R; Wu F; Feng X; Yu Y; Zhang HT; O'Donnell JM; Xu Y
Oncotarget; 2016 Apr; 7(14):17380-92. PubMed ID: 26980711
[TBL] [Abstract][Full Text] [Related]
13. PDE4 as a target for cognition enhancement.
Richter W; Menniti FS; Zhang HT; Conti M
Expert Opin Ther Targets; 2013 Sep; 17(9):1011-27. PubMed ID: 23883342
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus.
Zhang HT; Zhao Y; Huang Y; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2004 Aug; 29(8):1432-9. PubMed ID: 15114341
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Development of Phosphodiesterase-4 Inhibitors.
Peng T; Qi B; He J; Ke H; Shi J
J Med Chem; 2020 Oct; 63(19):10594-10617. PubMed ID: 32255344
[TBL] [Abstract][Full Text] [Related]
16. Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke.
Wang H; Gaur U; Xiao J; Xu B; Xu J; Zheng W
Int J Biol Sci; 2018; 14(12):1745-1754. PubMed ID: 30416389
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase-4 Inhibition in Parkinson's Disease: Molecular Insights and Therapeutic Potential.
Roy D; Balasubramanian S; Krishnamurthy PT; Sola P; Rymbai E
Cell Mol Neurobiol; 2023 Aug; 43(6):2713-2741. PubMed ID: 37074485
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4D: an enzyme to remember.
Ricciarelli R; Fedele E
Br J Pharmacol; 2015 Oct; 172(20):4785-9. PubMed ID: 26211680
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism.
Zhang HT; Crissman AM; Dorairaj NR; Chandler LJ; O'Donnell JM
Neuropsychopharmacology; 2000 Aug; 23(2):198-204. PubMed ID: 10882846
[TBL] [Abstract][Full Text] [Related]
20. RNA interference-mediated phosphodiesterase 4D splice variants knock-down in the prefrontal cortex produces antidepressant-like and cognition-enhancing effects.
Wang ZZ; Zhang Y; Liu YQ; Zhao N; Zhang YZ; Yuan L; An L; Li J; Wang XY; Qin JJ; Wilson SP; O'Donnell JM; Zhang HT; Li YF
Br J Pharmacol; 2013 Feb; 168(4):1001-14. PubMed ID: 23003922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
